

# **Self-tests for COVID-19: what is the evidence? A living systematic review and meta-analysis (2020-2023)**

Apoorva Anand<sup>1,2</sup>, Fiorella Vialard<sup>1,2,3</sup>, Aliasgar Esmail<sup>4</sup>, Faiz Ahmad Khan<sup>1,3</sup>, Patrick O’Byrne<sup>5</sup>, Jean-Pierre Routy<sup>2,3</sup>, Keertan Dheda<sup>4</sup>, Nitika Pant Pai<sup>1,2,3\*</sup>

<sup>1</sup>Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

<sup>2</sup>Infectious Diseases and Immunity in Global Health, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada

<sup>3</sup>Faculty of Medicine, McGill University, Montreal, Quebec, Canada

<sup>4</sup>Centre for Lung Infection and Immunity, Division of Pulmonology, UCT Lung Institute and Department of Medicine, University of Cape Town, Cape Town, Western Cape, South Africa

<sup>5</sup>Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada

**\*Corresponding author:**

E-mail: [nitika.pai@mcgill.ca](mailto:nitika.pai@mcgill.ca) (NPP)

**Short title: COVID-19 self-tests: a living systematic review and meta-analysis**

## 1 **Abstract**

2           COVID-19 self-testing strategy (COVIDST) can rapidly identify symptomatic and  
3 asymptomatic SARS-CoV-2-infected individuals and their contacts, potentially reducing  
4 transmission. In this living systematic review, we evaluated the evidence for real-world  
5 COVIDST performance. Two independent reviewers searched six databases (PubMed, Embase,  
6 Web of Science, World Health Organization database, Cochrane COVID-19 registry, Europe  
7 PMC) for the period April 1<sup>st</sup>, 2020, to January 18<sup>th</sup>, 2023. Data on studies evaluating COVIDST  
8 against laboratory-based conventional testing and reported on diagnostic accuracy, feasibility,  
9 acceptability, impact, and qualitative outcomes were abstracted. Bivariate random effects meta-  
10 analyses of COVIDST accuracy were performed (n=14). Subgroup analyses (by sampling site,  
11 symptomatic/asymptomatic infection, supervised/unsupervised strategy, with/without digital  
12 supports) were conducted. Data from 70 included studies, conducted across 25 countries with a  
13 median sample size of 817 (range: 28-784,707) were pooled. Specificity was high overall,  
14 irrespective of subgroups (98.37-99.71%). Highest sensitivities were reported for: a)  
15 symptomatic individuals (73.91%, 95%CI: 68.41-78.75%; n=9), b) mid-turbinate nasal samples  
16 (77.79%, 95%CI: 56.03-90.59%; n=14), c) supervised strategy (86.67%, 95%CI: 59.64-96.62%;  
17 n=13), and d) presence of digital interventions (70.15%, 95%CI: 50.18-84.63%; n=14).  
18 Sensitivity was lower in asymptomatic populations (40.18%, 95% CI: 21.52-62.20%; n=4), due  
19 to errors in test conduct and absence of supervision or a digital support. We found no difference  
20 in COVIDST sensitivity between delta and omicron pre-dominant period. Digital supports  
21 increased confidence in COVIDST reporting and interpretation (n=16). Overall acceptability was  
22 91.0-98.7% (n=2) with lower acceptability reported for daily self-testing (39.5-51.1%).

23 Feasibility was 69.0-100.0% (n=5) with lower feasibility (35.9-64.6%) for serial self-testing.  
24 COVIDST decreased closures in school, workplace, and social events (n=4). COVIDST is an  
25 effective rapid screening strategy for home-, workplace- or school-based screening, for  
26 symptomatic persons, and for preventing transmission during outbreaks. This data is useful for  
27 updating COVIDST policy. Our review demonstrates that COVIDST has paved the way for the  
28 introduction of self-tests, worldwide.

## 29 **Introduction**

30 COVID-19 cases are rapidly declining due to extensive vaccine coverage but clustering is  
31 reported in select subgroups (i.e., unvaccinated and immune suppressed individuals) [1]. A shift  
32 towards greater use of self-tests was observed towards the end of 2021. Widespread availability  
33 of rapid self-test kits, either through public distribution systems, or through private pharmacies,  
34 convenience stores, or online websites, empowered individuals to exercise autonomy in  
35 managing their exposures and guiding their actions.

36 COVID-19 self-testing strategies (COVIDST), are those where individuals collect their  
37 own samples, test themselves, interpret results, and use them to inform their actions post-self-  
38 test. COVIDST has particularly made the case for expanded access in the global north. However,  
39 it has greater value in areas with limited resources, in the setting of expensive/absent laboratory-  
40 based conventional testing, and in outbreaks [2].

41 COVIDST conducted with rapid diagnostic tests (RDTs) can detect active COVID-19  
42 infection in a rapid turnaround time (TAT), thereby offering a convenient, user-friendly  
43 alternative to conventional reverse transcription polymerase chain reaction (RT-PCR) tests.  
44 Conventional tests require long wait times and longer TATs with increased risk of COVID-19  
45 exposure [3, 4]. Alternatively, COVIDST can reduce dependence on healthcare workers (HCW)  
46 and reduce exposure in healthcare settings by allowing self-testing in safe, private spaces. Rapid  
47 identification of symptomatic SARS-CoV-2-infected individuals prevents exposure in  
48 community contacts and allows a timely knowledge of infection status, prompting informed  
49 action plans. Action plan initiation can greatly reduce transmission and mitigate burden on  
50 healthcare systems.

51           A Cochrane systematic review which assessed diagnostic accuracy of HCW-performed  
52 RDTs reported an average sensitivity of 72% in symptomatic individuals and 58% in  
53 asymptomatic individuals. However, researchers did not report outcomes beyond accuracy where  
54 RDTs were used as self-tests [5]. The World Health Organization (WHO) guidelines on  
55 COVIDST implementation released in early 2022 provide evidence on diagnostic accuracy [6].  
56 An explosion of literature in 2022-2023 on real world performance underscores the need for a  
57 comprehensive, living review of evidence beyond diagnostic performance.

58           The overarching goal of this living systematic review is to update existing policies, fill  
59 evidence gaps, and provide guidance to enhance quality of tests and reporting systems in line  
60 with WHO guidelines, and to guide future outbreaks of COVID-19.

61           The review aims to: a) explore variability in COVIDST diagnostic performance across  
62 the spectrum of its use in a meta-analysis; b) summarize feasibility, acceptability, accessibility,  
63 and public health impact of COVIDST; and c) document qualitative outcomes.

64

## 65 **Methods**

66           We registered our protocol on PROSPERO (CRD42022314799) [7]. No patients, study  
67 participants, or members of the public were involved in the design, conduct, or reporting of this  
68 review.

69

## 70 **Data sources and searches**

71           Two independent reviewers (AA, FV) searched five electronic databases (Pubmed,  
72 Embase, Web of Science, WHO database, and Cochrane COVID-19 registry) from April 1<sup>st</sup>,

73 2020, to January 18<sup>th</sup>, 2023, for peer-reviewed journal articles and conference abstracts. Grey  
74 literature was searched through the Europe PMC pre-prints database (Fig 1). No restrictions were  
75 placed on language or publication year. We will update the review until August 1<sup>st</sup>, 2023.

## 76 **Fig 1. PRISMA Flow diagram**

77

## 78 **Search string:**

79 *(COVID-19\* OR covid\* OR "SARS-CoV-2\*") AND*

80 *("Self-test\*" OR "Self test\*" OR "Self-screen\*" OR "Self screen\*" OR "home test\*" OR "at*  
81 *home test\*" OR "at-home test\*") (S1 Box).*

82

## 83 **Study selection**

84 All studies (observational and experimental) evaluating COVIDST strategies were  
85 included. Modelling studies, commentaries, narratives, opinion pieces, review articles, and case  
86 reports were excluded. Titles, abstracts, and full texts were independently screened for eligibility  
87 based on pre-specified inclusion and exclusion criteria. Disagreements were resolved by  
88 discussion and consultation with a senior reviewer (NPP) (Fig 1).

89

## 90 **Data extraction and quality assessment**

91 Data across all global geographic regions (low-, middle-, and high-income) were  
92 independently abstracted. Intervention included molecular/antigen/antibody COVID-19 self-  
93 tests. Comparators included conventional RT-PCR testing by HCWs or other trained  
94 professionals.

95 Primary outcome was diagnostic accuracy (i.e., sensitivity, specificity, and diagnostic  
96 odds ratio [DOR]) [8]. Authors were contacted for data when not completely available.

97 Secondary outcome data on feasibility, acceptability, new infections detection,  
98 preferences, and impact were abstracted and reported with summary estimates of proportions and  
99 95% confidence intervals (CI) [8, 9]. Tertiary outcomes included qualitative measures such as  
100 motivations, facilitators, and barriers. (S1 Table).

101 Quality Assessment of Diagnostic Accuracy Studies Tool 2 (QUADAS-2) was used to  
102 assess risk of bias in diagnostic accuracy studies (DAS). Newcastle-Ottawa Scale (NOS) was  
103 used for observational studies and Cochrane Risk of Bias Tool 2 (RoB2) for randomized  
104 controlled trials (RCTs) [10-14].

105

## 106 **Data synthesis and meta-analyses**

107 Diagnostic accuracy was explored in forest plots and heterogeneity was evaluated using  $i^2$   
108 metric. Using bivariate random-effects meta-analysis, variability in COVIDST performance  
109 across populations was explored.

110 Subgroup analyses were conducted for: 1) Symptom status (asymptomatic versus  
111 symptomatic individuals); 2) Strategy (supervised versus unsupervised testing strategy); 3) Site  
112 of self-sampling specimens (anterior nasal versus mid-turbinate nasal versus combined nasal-  
113 oropharyngeal versus saliva); 4) Digital support presence versus absence (i.e., websites,  
114 smartphone applications, test readers, other online tools).

115 All analyses were conducted in R statistical software using mada and meta packages [15,  
116 16].

117

## 118 **Results**

### 119 **Study selection**

120           Seventy studies (peer-reviewed=65, preprints=5) were included. Nine of these studies  
121 were retrieved through bibliographic search (Fig 1).

122

### 123 **Study characteristics**

124           Of seventy studies conducted across 25 countries, 63 (90.0%) were conducted in high-  
125 income countries (HICs) and eight (11.43%) in low- and middle-income countries (LMICs) [17].  
126 Three studies were conducted in multiple countries [3, 18, 19]. Sample sizes ranged from 28 to  
127 784,707 with a median sample size of 817. (S2 Table)

128           COVIDST strategies included mass screening (n=32), targeted screening (i.e., school,  
129 college, university, nursing home, sports club) (n=28), and healthcare facility-based screening  
130 (n=8).

131           Populations studied were: 1) general population members (n=39), 2) teachers, parents,  
132 school, and university students (n=11), 3) healthcare and laboratory staff (n=10), 4) hospital  
133 patients (n=5), 5) drug addiction treatment patients (n=1), 6) office employees (n=1), 7) nursing  
134 homes residents and staff (n=1), 8) music festival attendees (n=1), and 9) Black, Indigenous, and  
135 People of Colour (BIPOC) community (n=1).

136           Sampling sites used were anterior and mid-turbinate nasal, salivary, nasopharyngeal, and  
137 oropharyngeal.



138 Studies were conducted in asymptomatic (n=17), symptomatic (n=3), or both  
139 asymptomatic and symptomatic (n=27) individuals.

140 Thirty-four studies reported unsupervised/at-home self-testing strategy, ten studies  
141 evaluated supervised self-testing strategy, and two studies evaluated both. In supervised self-  
142 testing, the entire procedure was observed by trained HCWs or research staff, who may/may not  
143 intervene if it was incorrectly conducted or if assistance was required. In unsupervised  
144 COVIDST, unobserved testing was performed in testing centres or at-home.

145 Digital supports for COVIDST (n=20 studies) included websites, smartphone  
146 applications, and video-based instructions. Of these, nine studies reported digital components  
147 that aided in improving self-testing accuracy.

148

## 149 **Synthesized results for primary outcome (diagnostic accuracy)**

150 Diagnostic performance of COVIDST was evaluated in two ways: A) narrative synthesis  
151 and B) meta-analysis.

152 First, we reported sensitivity/specificity by test devices, symptom onset, covid variants,  
153 and cycle threshold (CT) values, for which we were unable to meta-analyze due to paucity of  
154 data and studies (Narrative synthesis, Primary outcome). We reported 95% confidence intervals  
155 (95% CIs) where available. Subsequently, we generated a forest plot from pooled sensitivity and  
156 specificity (n=14). For subgroups where data was available, we conducted a meta-analysis with  
157 pooled data (Meta-analysis results, Primary outcome).

158

## 159 **Narrative synthesis**

160 Diagnostic accuracy results from individual studies were summarized across test devices  
161 (n=14), by symptom onset (n=4), by CT value (n=3), and by variants (n=2). We could not  
162 perform a meta-analysis for these categories.

163 Four studies reported on diagnostic performance across 15 different COVIDST devices  
164 (S3 Table). Of these, four test devices reported WHO-recommended sensitivities above 80%:  
165 Boson SARS-CoV-2 antigen test card (98.18%, 95% CI: 96.74%–99.62%), Biosynex in  
166 symptomatic populations (93.8%; 95% CI: 79.3%–98.4%), Biosynex in asymptomatic  
167 populations (83.3%; 95% CI: 73.4%–90.0%), Standard Q by SD Biosensor (82.50%, 95% CI:  
168 68.1%–91.3% and 94.38%, 95% CI: 87.54%–98.60%), and MP Bio (83.01%, 95% CI: 78.8%–  
169 86.7%). Specificities were above 91% for all devices. [20-26].

170 Four studies reported accuracies by day of symptom onset. Two studies reported  
171 sensitivities of 99.18% one day prior to symptom onset, 98.77-100% on first 2 days, and 100%  
172 from day 2 to 7 of symptom onset [20, 25]. Conversely, a community-based study reported  
173 sensitivities of 23% within 0-1 days and 66.67% within 2-4 days of symptom onset [23]. Finally,  
174 another study reported a sensitivity of 73% when self-test was conducted within 0-5 days of  
175 symptom onset as compared to 22% when conducted after 5 days [27].

176 Three studies reported on self-test performance by cycle threshold (CT) values. Low CT  
177 values of positive RT-PCR results indicated a high viral load in swab samples. RT-PCR and self-  
178 test results were compared; CT value was checked for each self-test result. One study detected  
179 100% of infections with COVIDST when CT values were below 20, 92% when CT values were  
180 between 20-30, and 33.33% when CT values were above 30 [20]. COVIDST in 2 studies  
181 detected: 1) symptomatic cases when mean CT value was 23.1 (IQR: 19.5–30.0) and median CT

182 value was 14 (IQR: 12.0-18.0); 2) asymptomatic cases when mean CT value was 28.2 (IQR:  
183 25.0–33.0) [23, 28].

184 Two studies compared COVIDST performance in delta versus omicron variant infected  
185 populations. In one study, sensitivities decreased from 87.0% in the delta period to 80.9% in the  
186 omicron period [26]. Conversely, in another study, same-day sensitivity of self-tests was higher  
187 (22.1%, 95%CI: 15.5-28.8%) in omicron period versus 15.5% (95%CI: 6.2-24.8%) in delta  
188 period [29].

189

## 190 **Meta-analyses results**

191 Fourteen studies reported data on accuracy [19-26, 30-35]. First, we pooled sensitivities  
192 and specificities to create forest plots (S1 Fig A and B). Following this, we assessed  
193 heterogeneity and conducted subgroup analyses; results are summarized below.

194 Our forest plots reported a point estimate for pooled sensitivity (n=14) of 75.0% (95%CI:  
195 59.0%-86.0%) (S1 Fig A). Sensitivities varied from 25% to 98%. Random effects model  
196 heterogeneity  $i^2$  statistic was high at 97%. Point estimate for pooled specificity (n=14) was 100%  
197 (95%CI: 99.0%-100.0%) (S1 Fig B). Specificities varied from 97% to 100%. Random effects  
198 model heterogeneity  $i^2$  statistic was high at 94%.

199 We conducted subgroup analyses to explore this heterogeneity further. Summary receiver  
200 operating characteristic (SROC) curves were plotted for all subgroups (S2 Fig A-D). Pooled  
201 sensitivities, specificities, and DORs estimates are provided in Table 1.

202

### 203 **Table 1. Meta-analyses of COVIDST diagnostic accuracy**

204

Sr No	Category	Sub-groups	Sensitivity	95% CI	Specificity	95% CI	DOR	95% CI
1	Specific sampling site	Anterior nasal	63.8	46.68-78.00	99.29	98.73-99.60	263	123-497
		Mid-turbinate nasal	77.79	56.03-90.59	98.62	94.35-99.67	291	84.1-741
		Saliva	39.1	18.45-64.57	99.32	97.60-99.81	98.8	55.50-163.00
		Combined nasal-oropharyngeal	69.69	58.96-78.62	99.18	97.84-99.69	303	124-625
2	Symptomatic status	Symptomatic	73.91	68.41-78.75	98.37	97.47-98.95	175	108-270
		Asymptomatic	40.18	21.52-62.20	99.71	99.29-99.88	249	104-508
3	Testing method	Supervised	86.67	59.64-96.62	99.39	97.04-99.88	1530	200-5670
		Unsupervised	60.69	50.31-70.18	99.13	98.60-99.47	181	116-269
4	Digital Intervention	Present	70.15	50.08-84.63	99.39	97.99-99.82	409	193.00-764.00
		Absent	65.69	54.06-75.70	99.17	98.66-99.49	237	135-387

205

Significance code	P-value
***	[0, 0.001)
**	(0.001, 0.01)
*	(0.01, 0.05)
.	(0.05, 0.1)
	(0.1, 1)
Reference variable	

206

207

208

209

210

In subgroup analyses by sampling sites (n=14), highest sensitivity was reported in

samples from mid-turbinate sampling (77.79%, 95%CI: 56.03%-90.59%), followed by combined

nasal-oropharyngeal sampling (69.69%, 95%CI: 58.96%-78.62%), and anterior nasal sampling

211 (63.80%, 95%CI: 46.68%-78.0%, statistically significant). Sensitivity was lowest with salivary  
212 sampling (39.10%, 95%CI: 18.45%-64.57%). Specificity was above 98% irrespective of  
213 sampling site. DOR was highest for combined nasal-oropharyngeal specimens (303.00) and  
214 lowest for saliva specimens (98.80).

215         Nine out of fourteen studies reported diagnostic accuracy data based on presence/absence  
216 of symptoms. For symptomatic populations, sensitivity was 73.91% (95%CI: 68.41%-78.75%,  
217 statistically significant) versus 40.18% (95%CI: 21.52%-62.20%) for asymptomatic populations.  
218 Specificity was above 97% irrespective of symptomatic status. DOR was high at 249 for  
219 asymptomatic versus 175 in symptomatic populations.

220         Thirteen out of fourteen studies evaluated performance of supervised and unsupervised  
221 COVIDST. Supervised strategy reported a higher sensitivity of 86.67% (95%CI: 59.64%-  
222 96.62%) versus a sensitivity of 60.69% (95%CI: 50.31%-70.18%) in unsupervised strategy.  
223 Specificity was high at 99% irrespective of strategy. DOR was higher in supervised (1530.00)  
224 versus in unsupervised (181.00) COVIDST.

225         Fourteen studies analyzed COVIDST performance with/without digital supports.  
226 Sensitivity was higher with digital supports (70.15%, 95%CI: 50.08%-84.63%) than without  
227 (65.69%, 95%CI: 54.06%-75.70%). Specificity was 99% irrespective of presence/absence of  
228 digital supports. DOR was higher (409.00) with digital supports than without them (237.00).

229

## 230 **Synthesized results for secondary outcomes**

### 231 **Test positivity (new infections detected)**

232 Across twenty studies, new infections detected by COVIDST varied from 0.02% to 27%  
233 [22, 25, 27, 28, 31, 36-48]. In two other studies, test positivity varied from 12% to 83.3% during  
234 the delta wave and 41.7% to 87.2% during the omicron wave [29, 49]. Point prevalence for at-  
235 home COVIDST was 3.7% compared to 5.5% for testing by HCWs [47].

236

### 237 **Acceptability and willingness to use**

238 Thirteen studies reported an overall high acceptability and willingness to use COVIDST.  
239 COVIDST acceptability was high (91%-98.7%) in two studies, with higher acceptability in  
240 females (73.91%) versus males (60.09%) reported in another study [50-52]. Acceptability was  
241 lower (39.48%-51.1%) for daily self-testing [38, 40, 52]. Hesitancy to test (33.8%) and concerns  
242 about test accuracy (1%) made people decline COVIDST [40].

243 Across three studies in different populations, COVIDST uptake was 97% in school  
244 children, 92.5% in children with medical problems, and 45.2% in a mass self-testing study [41,  
245 43, 53]. Across seven studies, willingness to use nasal self-tests ranged from 77% to 95.8% [2,  
246 54-59].

247

### 248 **Feasibility and usability**

249 Eighteen studies reported high COVIDST feasibility and ease of use. Usability threshold,  
250 defined as the ability to correctly conduct all critical self-test steps, was higher with digital  
251 supports.

252 An overall high feasibility was reported (69.6%-100%) across five studies [23, 40, 45, 60,  
253 61]. In three studies, feasibility was lower for serial-testing COVIDST (35.9%-64.6%) [41, 50,

254 62]. The average completion rate was 4.3 self-tests over 4.8 weeks in another serial-testing study  
255 [62].

256 Across seven studies, participants found COVIDST easy to use (81%-100%) [22, 30, 34,  
257 45, 59, 63, 64]. Specifically, two studies reported a high ease of conducting at-home self-tests  
258 (95.7%), ease of reading self-test results (92%), and ease of remembering to test regularly (96%)  
259 [22, 38].

260 Across four studies, confidence in reporting test results and testing abilities was high  
261 (70%-98%) [30, 34, 38, 65]. Regular COVIDST by dentists improved perception of safety while  
262 treating patients by 49% [66].

263 Usability threshold was assessed in three studies. A high usability threshold was reported  
264 from Malawi (82.4%-90.4%) and Zimbabwe (65.4%-70.6%) [2]. In Germany, usability was  
265 61.2%, while in France, it increased from 99.1% to 100% with video supports [23, 67].

266

## 267 **Preference**

268 Across six studies, preference for COVIDST varied from 29% to 87.9% [32, 45, 51, 64,  
269 65, 67]. Overall, COVIDST preference was higher among white people, urban populations,  
270 political right, individuals with a college degree, and healthcare workers, as compared to ethnic  
271 minorities, rural populations, political left, individuals with a lower education, and working in  
272 other occupations [32, 51, 59, 63, 68, 69]. 94% of participants preferred throat swab-based self-  
273 test and 90% preferred saliva-based self-tests [55]. In another study, 95.4% participants preferred  
274 over-the-counter vending machines to obtain self-test kits [70].

275

## 276 **Impact outcomes**

277 Impact outcomes were evaluated in eighteen studies. In four studies, COVIDST reduced  
278 closures in different institutions and of public events. Regular COVIDST in a peri-urban primary  
279 school resulted in fewer school closures and decreased secondary infections in one study [71]. In  
280 another, daily mass COVIDST resulted in 8,292 workday savings of essential workers [41].

281 Self-tests were also used as daily testing tools in high exposure HCWs, allowing them to  
282 quarantine immediately in case of a positive result and prevent infection transmission [28]. In  
283 addition to healthcare settings, COVIDST facilitated the safe working of co-working health  
284 laboratory sites in a pandemic setting [31]. Furthermore, pre-event COVIDST allowed attendees  
285 to safely enjoy music concerts, wherein 87% of self-testers perceived a lower risk of contracting  
286 COVID-19 at the concert [72].

287 Three studies reported a higher TAT with COVIDST compared to conventional testing.  
288 In one study, TAT of 15-30 minutes for COVIDST versus 24-48 hours for RT-PCR was reported  
289 [22]. Antigen self-tests had a mean TAT of 8.1 minutes (standard deviation: 1.3) [23]. In another  
290 study, self-tests identified 23.5% of infections within 24 hours, and 54.9% of infections in the  
291 next 48 hours, prior to obtaining RT-PCR results.

292 Impact of COVIDST on action plans (n=7) and self-test result notification (n=4) was  
293 reported. In four studies, willingness to notify close contacts and relevant authorities was 80%-  
294 97.6% [2, 52, 54, 57]. In two studies, a high proportion of respondents (80.78%-98.32%) were  
295 willing to seek post-test counselling following a positive result [52, 57]. In three studies, 93%-  
296 100% testers expressed willingness to self-isolate following a positive test result [2, 57, 73].

297 Although only 49% of HCWs believed that self-testers would self-isolate themselves following a  
298 positive result, they opined that self-testers would take steps to reduce infection transmission [2].



299 Across two studies, 54%-78.3% of participants preferred validating initial COVIDST  
300 results through repeat testing [23, 54, 57]. In three studies, 70.1%-92.6% self-testers sought  
301 confirmatory RT-PCR testing [39, 41, 54]. Children aged 5-11 years and 12-18 years with a  
302 positive unsupervised self-test result were more likely to obtain a confirmatory PCR test  
303 compared to supervised testers (Odds ratio=3.48, 95%CI: 2.68-4.52 and Odds ratio=2.16,  
304 95%CI: 1.86-2.50, respectively) [36].

305

### 306 **Qualitative outcomes**

307 Qualitative outcomes such as motivations, facilitators, and barriers were assessed in 26  
308 studies.

309 Motivators to self-test were protecting one's health and reducing infection transmission to  
310 close contacts, partaking in daily activities and physically accessing services, workplace safety,  
311 travelling, dining outside, and attending large gatherings [45, 54, 67, 72, 74, 75]. Higher  
312 motivations to test were linked to a higher socioeconomic status (SES) and ability to acquire test  
313 kits [45, 69, 72, 74].

314 COVIDST facilitators assessed in twelve studies included self-test training prior to use,  
315 non-intrusive and ease of testing at-home, increased sense of safety, detailed self-test  
316 instructions, faster turnaround time, and instructional videos [23, 28, 32, 57, 61, 62, 67, 69, 71,  
317 76-80].

318 Across nine studies, COVIDST barriers included high costs, low trust in accuracy and  
319 reliability, anxiety, hesitation in self-test conduct, uncomfortable self-swabbing procedures,  
320 difficulty following instructions and interpreting faint positive test lines, lack of perceived  
321 benefit, and inequitable access to COVIDST [21-23, 53, 62, 79, 81-83].

322

### 323 **Self-testing with digital supports**

324 Across fifteen studies, COVIDST digital supports used were: online platforms (n=6),  
325 app-based COVIDST (n=6), video-based instructions (n=5), and online supervised COVIDST  
326 (n=6) [22-24, 32, 34, 38-40, 45, 46, 49-51, 59-62, 65, 72, 84].

327 In four studies, app-assisted COVIDST allowed 98%-100% of participants to  
328 successfully interpret their test results,[38, 50, 60, 84]. while video-taped self-testing process  
329 increased participants' confidence (76%) in COVIDST results [72].

330 In another four studies, uploading a test result picture or reporting test results online was  
331 a requirement that allowed HCWs to monitor and isolate positive cases [40, 49, 51, 60, 65].

332 In a mass COVIDST study, digital supports increased result notification in 75% of self-  
333 testers [84]. A self-testing and COVID-19 exposure notification app utilized such self-reported  
334 COVIDST results to reduce risk of infection in non-infected app users. [48, 49]. However,  
335 unincentivized and voluntary reporting with a digital assistant in one mass COVIDST study was  
336 low (4.6%) [84]. Also, digital reporting varied by test result; 3.2% reported positive test results  
337 and 1.8% reported negative test results [60]. One study reported that federal COVID-19 statistics  
338 did not include 42.8% of participants with a positive self-test result [48].

339

### 340 **Risk of bias assessment**

341 To assess any publication bias in studies included in the meta-analysis, a funnel plot was  
342 plotted (S3 Fig). A low risk of bias was estimated using Deek's method (p-value of 0.79).

343 Using the QUADAS-2 tool (n=14), we found low risk of bias across all categories except  
344 for reference standards (unclear risk, n=6) (S4 Table A). Cohort studies (n=13) had an average  
345 risk of bias in the comparability category (1-star, n=7) (S4 Table B). Similarly, cross-sectional  
346 studies (n=41) also had an average risk of bias in the comparability category (1-stars, n=12) (S4  
347 Table C). One case-control study had an overall poor risk of bias score across all categories.  
348 Finally, RoB2 tool was used for one qualitative RCT study wherein low risk for all domains was  
349 observed except for the selection of reported result domain.

350

## 351 **Discussion**

352 This review demonstrates that COVIDST strategies are effective in screening SARS-  
353 CoV-2 infections. Self-testing has a faster TAT compared to conventional testing, can be used in  
354 outbreak settings, prevent institutional closures, and reduce infection transmission in various  
355 settings.

356

## 357 **Diagnostic accuracy and caveats**

358 Our meta-analyses demonstrated very high specificity and above average sensitivity of  
359 COVIDST strategies.

360 Specificity for COVIDST (across all tests) was consistently above 98% regardless of  
361 different subgroups. Specificity is computed by calculating all true negatives (TN)/true negatives  
362 (TN) and false positives (FP). If the specificity is high, and the person is asymptomatic, we can  
363 be certain that the false positives are low.

364 In contrast, sensitivity for COVIDST varied across subgroups; highest sensitivities were  
365 reported for: a) mid-turbinate nasal specimens (77.79%, 95% CI: 56.03%-90.59%), b) tests  
366 conduct in supervised settings (86.67%, 95% CI: 59.64%-96.62%), c) symptomatic individuals  
367 (73.91%, 95% CI: 68.41%-78.75%), and d) digital COVIDST (70.15%, 95% CI: 50.08%-  
368 84.63%).

369 Sensitivity is computed by reporting true positives (TP)/true positives (TP) plus false  
370 negatives (FN). With that, if false negatives increase, sensitivity falls. In symptomatic  
371 individuals, highest sensitivities were reported for the first 5 days of symptom onset. In contrast,  
372 for asymptomatic individuals, sensitivities were consistently low (40.18%). Interpreting  
373 sensitivity and specificity is tricky at the population level, therefore simple messaging is very  
374 important for populations seeking to implement or use these self-tests. Our results show lower  
375 COVIDST sensitivity were due to unclear instructions for use, inadequate pre-test training,  
376 incorrect test conduct, non-adherence to instructions, and difficulties in interpreting faint positive  
377 test lines. To improve COVIDST performance, diagnostic companies need to design self-test kits  
378 with consideration for low-literacy and senior populations. Self-test instructions for conduct and  
379 interpretation must be detailed, comprehensive, and provided in layman terms. In areas with high  
380 digital literacy and data connectivity, video-based instructions and virtual pre-test training  
381 sessions can be provided.

382 Additionally, sensitivities were higher when CT value was lower or equal to 25. This is  
383 an important feature to note while sharing information on self-tests. Variance in sensitivity based  
384 on CT values show that self-tests can detect infections most accurately with peak viral loads and  
385 contagiousness. These findings highlight that the value of self-testing lies in the rapid  
386 identification and prompt isolation of highly contagious individuals compared to RT-PCR

387 positive tests. A median PCR positivity period of 22-33 days gives a positive test result in the  
388 presence of viral particles that persist even after resolution of infection.

389 Comparatively, most false negative self-test results occur when individuals are outside  
390 the transmissibility window [85]. If a COVIDST result is negative but an RT-PCR test result is  
391 positive, it is likely that the individual is not very infectious and may not pose a public health  
392 threat [85].

393 As for test devices used, some devices performed consistently as per WHO – for  
394 example, the Boson SARS-CoV-2 antigen test card, Biosynex, Standard Q at-home test, and MP  
395 Bio – while others did not (Please refer to Appendix table 3). Regarding strains, in the two  
396 studies that evaluated COVIDST performance by variants, we noted no difference in sensitivities  
397 for either the delta or the omicron strain pre-dominant periods. This is reassuring for future  
398 strains of the virus.

399

## 400 **Secondary and tertiary outcomes**

401 COVIDST screening strategies offer benefits in pandemic settings, when accessibility to  
402 laboratory testing is very limited, and timely test results are of the essence. Our results show that  
403 COVIDST strategies consistently reported a rapid TAT, were overall highly acceptable, highly  
404 feasible, and convenient to populations around the world. Their usability index was at 100% with  
405 additional digital supports. These supports included video-based or app-based instructions,  
406 highlighting the potential of digital COVIDST.

407 Our results are consistent with the interim guidance on self-testing provided by WHO,  
408 which found self-testing acceptable, feasible, and easy to use by laymen; however, our results are

409 updated and include data that can serve WHO to adapt their guidance. These results were also  
410 very similar to the proven benefits that have been demonstrated with HIV self-testing [86].

411 Despite established COVID-19 nucleic acid amplification testing (NAAT) surveillance  
412 systems in many countries, COVIDST became an important screening and decision-making tool  
413 for individuals during the peak of the pandemic [87]. Our results show that regular COVIDST  
414 was instrumental in impacting onward transmission that stemmed from the pandemic. This  
415 impact was demonstrated in reducing school closures, resuming in-person education, and  
416 allowed attendees to safely attend social events. Healthcare workers were able to treat patients  
417 while monitoring themselves, thereby reducing the risk of nosocomial infections.

418 Serial testing during the pandemic, especially in high exposure jobs, allowed essential  
419 workers to resume work without fear of losing pay and laboratories were able to remain  
420 operational. Participants were willing to report results, adhere to self-isolation guidelines, and  
421 seek confirmatory testing following a positive self-test result. Periodic self-testing reduced  
422 anxiety and created an environment of safety and reassurance when resuming normal activities.

423 Overall, participants were motivated to use COVIDST strategies to know their infection  
424 status, resume daily activities, protect their loved ones, and exercise caution while attending  
425 large gatherings. Motivations and preference for COVIDST over lab-based testing increased with  
426 a higher SES and in urban areas.

427 Inequitable access to self-tests in ethnic minorities with a lower SES was observed. This  
428 alludes to inequity in distribution of self-tests that was largely restricted to those with resources.  
429 This pattern could be changed for future pandemics by reducing the unit price of self-tests and  
430 public procurement of tests for large scale use.

431 Evidence on COVIDST parallels the vast evidence that has accumulated for HIVST.

432 Both viruses have paved the way for a greater use of self-testing solutions to know serostatus,  
433 and by increasing accessibility offered by these solutions during the pandemic, have made self-  
434 tests a common household name. This strategy holds promise for many infectious pathogens and  
435 pandemics.

436

## 437 **Strengths and limitations**

438 To our knowledge, ours is the first comprehensive and updated systematic review and  
439 meta-analysis on COVIDST. Although WHO released COVIDST guidelines, data on diagnostic  
440 accuracy then were scarce, so meta-analyses could not be performed. Additionally, these  
441 guidelines were based on studies published before February 2022 while our updated review  
442 contains recent studies (2023) that complement these results.

443 Our review is based on observational data. With a few RCTs underway, new data will  
444 soon become available [88, 89]. Most of the data are from HICs (n=63), making our results  
445 difficult to generalize to LMICs. Finally, no studies were reported with highly accurate  
446 molecular rapid COVIDST strategies [90].

447

## 448 **Implication for product development and research**

449 Publicly distributed self-tests can guarantee widespread accessibility but should be  
450 implemented with evidence-based strategies to improve test conduct and result interpretation.  
451 Checks for counterfeit test kits are necessary and regulating the sales of COVIDST kits can help  
452 improve public confidence in self-testing.

453 Public health sector and not-for-profit organizations along with healthcare facilities and  
454 pharmacies can increase access to self-tests by free-of-cost, widespread distribution of kits in  
455 urban and rural areas.

456 A strong and connected reporting system must be implemented by local authorities to  
457 avoid underestimating the true burden of infections. Future research can explore COVIDST  
458 diagnostic performance with digitally connected platforms, apps, test readers, and systems to  
459 report message notification and linkage to care. Data from clinical trials are needed to fill the  
460 gaps in evidence from LMICs.

461

## 462 **Conclusion**

463 Self-testing complements conventional testing in the pandemic setting with its speed and  
464 efficiency when time is of the essence. Our review demonstrates that COVIDST is a convenient  
465 and effective strategy for screening infections when used by the general population.

466 In symptomatic populations, in supervised settings with guided instructions, and with the  
467 addition of digital supports, self-tests improved in their performance. COVIDST had a high  
468 usability threshold, impacted institutional closures, and reported results notification where  
469 reporting systems were in place. However, data from LMICs were limited due to scarcity of self-  
470 testing.

471 Digital COVIDST is promising, and additional data will help improve accuracy and trust.  
472 Our results can aid policymakers, government bodies, and healthcare systems in updating their  
473 policies, and organizations aimed at integrating triple self-testing strategies in their health



474 ecosystems. COVIDST can alleviate the impact of the COVID-19 pandemic across all global  
475 settings and their widespread availability will help address global health inequities.

476 Both HIVST and COVIDST have demonstrated the impact that self-tests can have in  
477 empowering lay individuals to know their serostatus and in preventing forward transmission.  
478 This approach holds promise for the many self-tests for related pathogens (HCV, HBV, Syphilis,  
479 and MPox), and use of this tool can aid in ending future waves of these pandemics.

480

## 481 **Acknowledgements**

482 The authors would like to thank Olivia Vaikla for her assistance with proofreading and  
483 formatting the manuscript.

484

## 485 **Authors' contributions**

486 AA and NPP designed, drafted, and reviewed the initial manuscript while the remaining  
487 authors (FV, FK, AE, POB, JPR, KD) provided critique on subsequent drafts. Search strategy  
488 was developed and executed by AA, FV, and NPP. Data abstraction and quality assessment were  
489 performed by AA and FV. All authors (AA, FV, FK, AE, POB, JPR, KD, NPP) have reviewed  
490 and approved the final written manuscript.

491

## 492 **Data availability**

493 All data relevant to the study are included in the article or uploaded as supplementary  
494 information.

## 495 **References**

- 496 1. COVID-19 Situation Reports: The World Health Organization; 2022. Available  
497 from: [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---9-november-2022)  
498 [19---9-november-2022](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---9-november-2022).
- 499 2. Use of SARS-CoV-2 antigen rapid diagnostic tests for COVID19 self-testing  
500 INTERIM GUIDANCE- Web Annex B.: The World Health Organization; 2022. Available  
501 from: [https://apps.who.int/iris/bitstream/handle/10665/352345/WHO-2019-nCoV-Ag-](https://apps.who.int/iris/bitstream/handle/10665/352345/WHO-2019-nCoV-Ag-RDTs-Self-testing-Web-annex-B-2022.1-eng.pdf)  
502 [RDTs-Self-testing-Web-annex-B-2022.1-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/352345/WHO-2019-nCoV-Ag-RDTs-Self-testing-Web-annex-B-2022.1-eng.pdf).
- 503 3. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-  
504 testing: The World Health Organization; 2022. Available from:  
505 [https://www.who.int/publications/i/item/WHO-2019-nCoV-Ag-RDTs-Self\\_testing-2022.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Ag-RDTs-Self_testing-2022.1).
- 506 4. Procop GW, Kadkhoda K, Rhoads DD, Gordon SG, Reddy AJ. Home testing for  
507 COVID-19: Benefits and limitations. *Cleve Clin J Med*. 2021. doi:  
508 10.3949/ccjm.88a.ccc071.
- 509 5. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid,  
510 point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.  
511 *Cochrane Database Syst Rev*. 2021;3(3):CD013705-CD. doi:  
512 10.1002/14651858.CD013705.pub2. PubMed PMID: 33760236.
- 513 6. Web Annex A. GRADE table: Should COVID-19 self-testing,  
514 using SARS-CoV-2 Ag-RDTs, be offered as an additional  
515 approach? : The World Health Organization; 2022. Available from:  
516 [https://apps.who.int/iris/bitstream/handle/10665/352344/WHO-2019-nCoV-Ag-RDTs-](https://apps.who.int/iris/bitstream/handle/10665/352344/WHO-2019-nCoV-Ag-RDTs-Self-testing-Web-annex-A-2022.1-eng.pdf)  
517 [Self-testing-Web-annex-A-2022.1-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/352344/WHO-2019-nCoV-Ag-RDTs-Self-testing-Web-annex-A-2022.1-eng.pdf).
- 518 7. Apoorva A, Nitika PP, Fiorella V, Faiz AK, Ali E, Patrick OB, et al. Diagnostic  
519 performance, feasibility, and real-world evaluation of COVID-19 self-tests: A living  
520 systematic review & meta-analysis protocol [Protocol]. PROSPERO-International  
521 prospective register of systematic reviews; 2022.
- 522 8. Pant Pai N, Sharma J, Shivkumar S, Pillay S, Vadnais C, Joseph L, et al.  
523 Supervised and unsupervised self-testing for HIV in high- and low-risk populations: a  
524 systematic review. *PLoS Med*. 2013;10(4):e1001414-e. Epub 2013/04/02. doi:  
525 10.1371/journal.pmed.1001414. PubMed PMID: 23565066.

- 526 9. Pant Pai N, Chiavegatti T, Vijh R, Karatzas N, Daher J, Smallwood M, et al.  
527 Measures and Metrics for Feasibility of Proof-of-Concept Studies With Human  
528 Immunodeficiency Virus Rapid Point-of-Care Technologies: The Evidence and the  
529 Framework. *Point Care*. (1533-029X (Print)). doi: 10.1097/POC.000000000000147.
- 530 10. Penny FW, Anne W S R, Marie E W, Susan M, Jonathan J D, Johannes B R, et  
531 al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.  
532 *Ann Intern, Med*. (1539-3704 (Electronic)). doi: 10.7326/0003-4819-155-8-201110180-  
533 00009.
- 534 11. G A W, B S, D OC, J P, V W, M L, et al. The Newcastle-Ottawa Scale (NOS) for  
535 assessing the quality of nonrandomised studies in meta-analyses 2011. Available from:  
536 [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
- 537 12. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials: Cochrane  
538 Methods. Available from: [https://methods.cochrane.org/bias/resources/rob-2-revised-  
539 cochrane-risk-bias-tool-randomized-  
540 trials#:~:text=Version%20%20of%20the%20Cochrane,design%2C%20conduct%2C%  
541 20and%20reporting](https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials#:~:text=Version%20%20of%20the%20Cochrane,design%2C%20conduct%2C%20and%20reporting).
- 542 13. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al.  
543 Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-  
544 Analysis. *PLoS one*. 2016;11(1):e0147601. doi: 10.1371/journal.pone.0147601.
- 545 14. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al.  
546 Panethnic differences in blood pressure in europe: a systematic review and meta-  
547 analysis- S1: NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE  
  
548 (adapted for cross sectional studies). *PLoS one*. 2016. doi:  
549 10.1371/journal.pone.0147601.
- 550 15. Philipp D, Heinz H, Bernardo S-P. Meta-Analysis of Diagnostic Accuracy with  
551 mada: The Comprehensive R Archive Network. Available from: [https://cran.r-  
552 project.org/web/packages/mada/vignettes/mada.pdf](https://cran.r-project.org/web/packages/mada/vignettes/mada.pdf).
- 553 16. Schwarzer G. General Package for Meta-Analysis: The Comprehensive R  
554 Archive Network. Available from: <https://cran.r-project.org/web/packages/meta/meta.pdf>.
- 555 17. The World by Income and Region: The World Bank; 2021. Available from:  
556 [https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-  
557 and-region.html](https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html).
- 558 18. Boulliat C, Bilong CV, Dussart C, Massoubre B. Use of self-tests and rapid  
559 diagnostic tests: Survey of dispensing pharmacists in the Auvergne-Rhone-Alpes

- 560 region. *Ann Pharm Fr.* 2021;79(5):547-57. doi:  
561 <http://dx.doi.org/10.1016/j.pharma.2021.01.011>. PubMed PMID: 2011983076.
- 562 19. García-Fiñana M, Hughes DM, Cheyne CP, Burnside G, Stockbridge M, Fowler  
563 TA, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the  
564 Liverpool asymptomatic testing pilot: population based cohort study. *BMJ.*  
565 2021;374:n1637. doi: 10.1136/bmj.n1637.
- 566 20. Kim S, Choi W. Performance of standard q covid-19 ag home test to detect sars-  
567 cov-2 within five days of disease onset. *Clin Chem Lab Med.* 2021;59(SUPPL 1):S606.  
568 doi: <http://dx.doi.org/10.1515/cclm-2021-5027>. PubMed PMID: 636561836.
- 569 21. Lindner AK, Nikolai O, Rohardt C, Kausch F, Wintel M, Gertler M, et al.  
570 Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-  
571 detecting rapid test. *J Clin Virol.* 2021;141 (no pagination). doi:  
572 <http://dx.doi.org/10.1016/j.jcv.2021.104874>. PubMed PMID: 2013057417.
- 573 22. Schuit E, Venekamp R, Veldhuijzen I, van den Bijllaardt W, Pas S, Stohr J, et al.  
574 Accuracy and usability of saliva and nasal rapid antigen self-testing for detection of  
575 SARS-CoV-2 infection in the general population: a head-to-head comparison. *medRxiv.*  
576 2021. doi: 10.1101/2021.12.08.21267452. PubMed PMID: PPR431858.
- 577 23. Tonen-Wolyec S, Dupont R, Awaida N, Batina-Agasa S, Hayette MP, Belec L.  
578 Evaluation of the practicability of biosynex antigen self-test covid-19 ag+ for the  
579 detection of sars-cov-2 nucleocapsid protein from self-collected nasal mid-turbinate  
580 secretions in the general public in france. *Diagnostics.* 2021;11(12) (no pagination). doi:  
581 <http://dx.doi.org/10.3390/diagnostics11122217>. PubMed PMID: 2014709998.
- 582 24. Zwart VF, van der Moeren N, Stohr JJM, Feltkamp MCW, Bentvelsen RG,  
583 Diederer BMW, et al. Performance of Various Lateral Flow SARS-CoV-2 Antigen Self  
584 Testing Methods in Healthcare Workers: a Multicenter Study. *medRxiv.* 2022. doi:  
585 10.1101/2022.01.28.22269783. PubMed PMID: PPR447982.
- 586 25. Leventopoulos M, Michou V, Papadimitropoulos M, Vourva E, Manias NG,  
587 Kavvadas HP, et al. Evaluation of the Boson rapid Ag test vs RT-PCR for use as a self-  
588 testing platform. *Diagn Microbiol Infect Dis.* 2022;104(3):115786. Epub 20220729. doi:  
589 10.1016/j.diagmicrobio.2022.115786. PubMed PMID: 35998553; PubMed Central  
590 PMCID: PMC9335347.
- 591 26. Schuit E, Venekamp RP, Hooft L, Veldhuijzen IK, van den Bijllaardt W, Pas SD,  
592 et al. Diagnostic accuracy of covid-19 rapid antigen tests with unsupervised self-  
593 sampling in people with symptoms in the omicron period: cross sectional study. *Bmj.*  
594 2022;378:e071215. Epub 20220914. doi: 10.1136/bmj-2022-071215. PubMed PMID:  
595 36104069; PubMed Central PMCID: PMC9471225.

- 596 27. Bae S, Park H, Kim JY, Park S, Lim SY, Bae JY, et al. Daily, self-test rapid  
597 antigen test to assess SARS-CoV-2 viability in de-isolation of patients with COVID-19.  
598 Front Med (Lausanne). 2022;9:922431. Epub 20221019. doi:  
599 10.3389/fmed.2022.922431. PubMed PMID: 36341265; PubMed Central PMCID:  
600 PMCPMC9627621.
- 601 28. Downs LO, Eyre DW, O'Donnell D, Jeffery K. Home-based SARS-CoV-2 lateral  
602 flow antigen testing in hospital workers. J Infect. (1532-2742 (Electronic)). doi:  
603 10.1016/j.jinf.2021.01.008. PubMed Central PMCID: PMCPMC7870106.
- 604 29. Soni A, Herbert C, Filippaios A, Broach J, Colubri A, Fahey N, et al. Comparison  
605 of Rapid Antigen Tests' Performance between Delta (B.1.61.7; AY.X) and Omicron  
606 (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home  
607 Self-Testing Study. J Intern Med. 2022. doi: <https://doi.org/10.7326/M22-0760>.
- 608 30. Frediani JK, Levy JM, Rao A, Bassit L, Figueroa J, Vos MB, et al.  
609 Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care  
610 antigen test in the context of emerging viral variants and self-administration. Sci Rep.  
611 2021;11(1):14604. Epub 20210716. doi: 10.1038/s41598-021-94055-1. PubMed PMID:  
612 34272449; PubMed Central PMCID: PMCPMC8285474.
- 613 31. Harmon A, Chang C, Salcedo N, Sena B, Herrera BB, Bosch I, et al. Validation of  
614 an At-Home Direct Antigen Rapid Test for COVID-19. JAMA Netw Open.  
615 2021;4(8):e2126931. Epub 20210802. doi: 10.1001/jamanetworkopen.2021.26931.  
616 PubMed PMID: 34448871; PubMed Central PMCID: PMCPMC8397931.
- 617 32. Møller IJB, Utke AR, Ryesgaard UK, Østergaard LJ, Jespersen S. Diagnostic  
618 Performance, User Acceptability, and Safety of Unsupervised SARS-CoV-2 Rapid  
619 Antigen Detecting Tests Performed at Home. Int J Infect Dis. 2021. doi:  
620 10.1016/j.ijid.2022.01.019
- 621 33. Tim P, UK C-LFOT. COVID-19: Rapid Antigen detection for SARS-CoV-2 by  
622 lateral flow assay: a national systematic evaluation for mass-testing. medRxiv.  
623 2021:2021.01.13.21249563. doi: <https://doi.org/10.1101/2021.01.13.21249563>.
- 624 34. Stohr J, Zwart VF, Goderski G, Meijer A, Nagel-Imming CRS, Kluytmans-van den  
625 Bergh MFQ, et al. Self-testing for the detection of SARS-CoV-2 infection with rapid  
626 antigen tests for people with suspected COVID-19 in the community. Clin Microbiol  
627 Infect. 2021. Epub 20210804. doi: 10.1016/j.cmi.2021.07.039. PubMed PMID:  
628 34363945; PubMed Central PMCID: PMCPMC8336990.
- 629 35. Venekamp RP, Schuit E, Hooft L, Veldhuijzen IK, van den Bijllaardt W, Pas SD,  
630 et al. Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic  
631 individuals in the omicron period: a cross-sectional study. Clin Microbiol Infect. 2022.

- 632 Epub 20221113. doi: 10.1016/j.cmi.2022.11.004. PubMed PMID: 36379401; PubMed  
633 Central PMCID: PMCPMC9659357.
- 634 36. Hughes DM, Bird SM, Cheyne CP, Ashton M, Campbell MC, García-Fiñana M, et  
635 al. Rapid antigen testing in COVID-19 management for school-aged children: an  
636 observational study in Cheshire and Merseyside, UK. *J Public Health (Oxf)*. 2022. Epub  
637 20220204. doi: 10.1093/pubmed/fdac003. PubMed PMID: 35137216.
- 638 37. Cassuto NG, Gravier A, Colin M, Theillay A, Pires-Roteira D, Pallay S, et al.  
639 Evaluation of a SARS-CoV-2 antigen-detecting rapid diagnostic test as a self-test:  
640 Diagnostic performance and usability. *J Med Virol*. 2021;93(12):6686-92. Epub  
641 20210826. doi: 10.1002/jmv.27249. PubMed PMID: 34331707; PubMed Central  
642 PMCID: PMCPMC8426870.
- 643 38. Hirst JA, Logan M, Fanshawe TR, Mwandigha L, Wanat M, Vicary C, et al.  
644 Feasibility and Acceptability of Community Coronavirus Disease 2019 Testing  
645 Strategies (FACTS) in a University Setting. *Open Forum Infect Dis*. 2021;8(12):ofab495.  
646 Epub 20211004. doi: 10.1093/ofid/ofab495. PubMed PMID: 34904117; PubMed Central  
647 PMCID: PMCPMC8515264.
- 648 39. Lamb G, Heskin J, Randell P, Mughal N, Moore LS, Jones R, et al. Real-world  
649 evaluation of COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at  
650 a London hospital; a prospective cohort analysis. *J Infect*. 2021;83(4):452-7. doi:  
651 <http://dx.doi.org/10.1016/j.jinf.2021.07.038>. PubMed PMID: 2014190661.
- 652 40. Love N, Ready D, Turner C, Yardley L, Rubin GJ, Hopkins S, et al. The  
653 acceptability of testing contacts of confirmed COVID-19 cases using serial, self-  
654 administered lateral flow devices as an alternative to self-isolation. *J Med Microbiol*.  
655 2021. doi: <https://doi.org/10.1099/jmm.0.001567>.
- 656 41. Institute of Population Health UoL. Covid-SMART Asymptomatic Testing  
657 Pilot in Liverpool City Region:  
658 Quantitative Evaluation 2022. Available from:  
659 [https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool\\_City\\_Region\\_Covid\\_S  
660 MART\\_Evaluation-Feb.pdf](https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool_City_Region_Covid_SMART_Evaluation-Feb.pdf).
- 661 42. Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Nash D. Estimating the  
662 Period Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-  
663 2) Infection During the Omicron (BA.1) Surge in New York City (NYC), 1 January to 16  
664 March 2022. *Clin Infect Dis*. doi: 10.1093/cid/ciac644. PubMed PMID:  
665 WOS:000848015700001.

- 666 43. Coller RJ, Kelly MM, Howell KD, Warner G, Butteris SM, Ehlenbach ML, et al. In-  
667 Home COVID-19 Testing for Children with Medical Complexity: Feasibility and  
668 Association With School Attendance and Safety Perceptions. *Am J Public Health*.  
669 2022:e1-e5. Epub 20220915. doi: 10.2105/ajph.2022.306971. PubMed PMID:  
670 36108256.
- 671 44. Papenburg J, Campbell JR, Caya C, Dion C, Corsini R, Cheng MP, et al.  
672 Adequacy of Serial Self-performed SARS-CoV-2 Rapid Antigen Detection Testing for  
673 Longitudinal Mass Screening in the Workplace. *JAMA Netw Open*. 2022;5(5):e2210559.  
674 Epub 20220502. doi: 10.1001/jamanetworkopen.2022.10559. PubMed PMID:  
675 35522284; PubMed Central PMCID: PMC9077488.
- 676 45. Agustí C, Martínez-Riveros H, González V, Fernández-Rivas G, Díaz Y,  
677 Montoro-Fernandez M, et al. Feasibility of an online antigen self-testing strategy for  
678 SARS-CoV-2 addressed to health care and education professionals in Catalonia  
679 (Spain). The TESTA'T- COVID Project. *PLoS One*. 2022;17(9):e0275006. Epub  
680 20220927. doi: 10.1371/journal.pone.0275006. PubMed PMID: 36166432; PubMed  
681 Central PMCID: PMC9514624.
- 682 46. O'Byrne P, Orser L, Musten A, Ho N, Haines M, Lindsay J. Delivering COVID  
683 self-tests through GetaKit.ca: Creating testing access during a pandemic. *Public Health*  
684 *Nurs*. 2023. Epub 20230110. doi: 10.1111/phn.13168. PubMed PMID: 36625331.
- 685 47. Qasmieh SA, Robertson MM, Rane MS, Shen Y, Zimba R, Picchio CA, et al. The  
686 Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence  
687 Estimates: Findings From a US National Cohort, February 2022. *JMIR Public Health*  
688 *Surveill*. 2022;8(12):e38196. Epub 20221227. doi: 10.2196/38196. PubMed PMID:  
689 36240020; PubMed Central PMCID: PMC9822564.
- 690 48. Stemler J, Salmanton-García J, Weise B, Többen C, Joisten C, Fleig J, et al. A  
691 pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in  
692 Germany, 1st week of July 2022. *Infection*. 2022;1-5. Epub 20221024. doi:  
693 10.1007/s15010-022-01931-7. PubMed PMID: 36279033; PubMed Central PMCID:  
694 PMC9590393.
- 695 49. Daniore P, Nittas V, Ballouz T, Menges D, Moser A, Höglinger M, et al.  
696 Performance of the Swiss Digital Contact-Tracing App Over Various SARS-CoV-2  
697 Pandemic Waves: Repeated Cross-sectional Analyses. *JMIR Public Health Surveill*.  
698 2022;8(11):e41004. Epub 20221111. doi: 10.2196/41004. PubMed PMID: 36219833;  
699 PubMed Central PMCID: PMC9700234.
- 700 50. Herbert C, Broach J, Heetderks W, Qashu F, Gibson L, Pretz C, et al. At-Home  
701 Serial Testing Using Over-the-Counter SARS-CoV-2 Tests with a Digital Smartphone  
702 App for Assistance: Findings of feasibility from a longitudinal cohort study. *JMIR Form*  
703 *Res*. 2022. Epub 20220825. doi: 10.2196/35426. PubMed PMID: 36041004.

- 704 51. Martin AF, Denford S, Love N, Ready D, Oliver I, Amlôt R, et al. Engagement  
705 with daily testing instead of self-isolating in contacts of confirmed cases of SARS-CoV-  
706 2. BMC public health. 2021;21(1):1067. doi: 10.1186/s12889-021-11135-7.
- 707 52. Martinez-Perez GZ, Shilton S, Sarue M, Cesario H, Banerji A, Batheja D, et al.  
708 Self-testing for SARS-CoV-2 in Sao Paulo, Brazil: results of a population-based values  
709 and attitudes survey. BMC Infect Dis. 2022;22(1). doi: 10.1186/s12879-022-07706-7.  
710 PubMed PMID: WOS:000849202400001.
- 711 53. Marinos G, Lamprinos D, Georgakopoulos P, Oikonomou E, Zoumpoulis G,  
712 Garpis N, et al. Evaluation of Knowledge, Attitudes and Practices Related to Self-  
713 Testing Procedure against COVID-19 among Greek Students: A Pilot Study. Int J  
714 Environ Res Public Health. 2022;19(8). Epub 20220410. doi: 10.3390/ijerph19084559.  
715 PubMed PMID: 35457427; PubMed Central PMCID: PMC9026819.
- 716 54. Betsch C, Sprengholz P, Siegers R, Eitze S, Korn L, Goldhahn L, et al. Empirical  
717 evidence to understand the human factor for effective rapid testing against SARS-CoV-  
718 2. Proc Natl Acad Sci USA. 2021;118(32). doi: 10.1073/pnas.2107179118. PubMed  
719 PMID: 34362848; PubMed Central PMCID: PMC9026819.
- 720 55. Mistler CB, Sullivan M, Wickersham JA, Copenhaver MM, Shrestha R. Clinical  
721 and demographic differences in the willingness to use self-administered at-home  
722 COVID-19 testing measures among persons with opioid use disorder. Subst Abus.  
723 2022;43(1):708-12. doi: 10.1080/08897077.2021.2007511. PubMed PMID: 35100084.
- 724 56. Phillips G, Xu JY, Ruprecht MM, Costa D, Felt D, Wang XZ, et al. Associations  
725 with COVID-19 Symptoms, Prevention Interest, and Testing Among Sexual and Gender  
726 Minority Adults in a Diverse National Sample. LGBT Health. 2021;8(5):322-9. doi:  
727 10.1089/lgbt.2021.0002. PubMed PMID: WOS:000660215700001.
- 728 57. Thomas C, Shilton S, Thomas C, Batheja D, Goel S, Iye CM, et al. Values and  
729 preferences of the general population in Indonesia in relation to COVID-19 self-testing:  
730 A cross-sectional survey. Trop Med Int Health. 2022. doi: 10.1111/tmi.13748.
- 731 58. LeRouge C, Durneva P, Lyon V, Thompson M. Health Consumer Engagement,  
732 Enablement, and Empowerment in Smartphone-Enabled Home-Based Diagnostic  
733 Testing for Viral Infections: Mixed Methods Study. JMIR Mhealth Uhealth.  
734 2022;10(6):e34685. Epub 20220630. doi: 10.2196/34685. PubMed PMID: 35771605;  
735 PubMed Central PMCID: PMC9284354.
- 736 59. Schilling J, Moeller FG, Peterson R, Beltz B, Joshi D, Gartner D, et al. Testing  
737 the Acceptability and Usability of an AI-Enabled COVID-19 Diagnostic Tool Among  
738 Diverse Adult Populations in the United States. Qual Manag Health Care.  
739 2023;32(Suppl 1):S35-s44. doi: 10.1097/qmh.0000000000000396. PubMed PMID:  
740 36579707; PubMed Central PMCID: PMC9811483.



- 741 60. Herbert C, Kheterpal V, Suvarna T, Broach J, Marquez JL, Gerber B, et al.  
742 Design and Preliminary Findings of Adherence to the Self-Testing for Our Protection  
743 From COVID-19 (STOP COVID-19) Risk-Based Testing Protocol: Prospective Digital  
744 Study. *JMIR Form Res.* 2022;6(6):e38113. Epub 20220616. doi: 10.2196/38113.  
745 PubMed PMID: 35649180; PubMed Central PMCID: PMC9205422.
- 746 61. Hoehl S, Schenk B, Rudych O, Göttig S, Foppa I, Kohmer N, et al. High-  
747 Frequency Self-Testing by Schoolteachers for Sars-Cov-2 Using a Rapid Antigen Test–  
748 Results of the Safe School Hesse study. *Dtsch Arztebl Int.* 2021;118(14):252-3. doi:  
749 10.3238/arztebl.m2021.0187. PubMed PMID: 34114556; PubMed Central PMCID:  
750 PMC9283684.
- 751 62. Wanat M, Logan M, Hirst J, Vicary C, Lee JJ, Perera R, et al. Perceptions on  
752 undertaking regular asymptomatic self-testing for COVID-19 using lateral flow tests: A  
753 qualitative study of university students and staff. *BMJ Open.* 2021. doi:  
754 <http://dx.doi.org/10.1136/bmjopen-2021-053850>.
- 755 63. Prazuck T, Gravier A, Pires-Roteira D, Theillay A, Pallay S, Colin M, et al.  
756 Evaluation Of A New “All In One” Sars-Cov-2 Antigen-Detecting Rapid Diagnostic Test  
757 And Self-Test: Diagnostic Performance And Usability On Child And Adult Population. *J*  
758 *Med Virol.* 2021. doi: <https://doi.org/10.1002/jmv.27812>. PubMed PMID: PPR400123.
- 759 64. Prazuck T, Gravier A, Pires-Roteira D, Theillay A, Pallay S, Colin M, et al.  
760 Evaluation of a new "all in one" SARS-CoV-2 antigen-detecting rapid diagnostic test and  
761 self-test: Diagnostic performance and usability in child and adult populations. *J Med*  
762 *Virol.* 2022;94(9):4097-106. Epub 20220525. doi: 10.1002/jmv.27812. PubMed PMID:  
763 35474460; PubMed Central PMCID: PMC9088384.
- 764 65. Denford S, Martin A, Love N, Ready D, Oliver I, Amlôt R, et al. Engagement with  
765 daily testing instead of self-isolating in contacts of confirmed cases of SARS-CoV-2: A  
766 qualitative analysis. *Front Public Health.* 2021. doi:  
767 <https://doi.org/10.3389/fpubh.2021.714041>. PubMed PMID: PPR348017.
- 768 66. Coker MO, Subramanian G, Davidow A, Fredericks-Younger J, Gennaro ML,  
769 Fine DH, et al. Impact of DHCWs' Safety Perception on Vaccine Acceptance and  
770 Adoption of Risk Mitigation Strategies. *JDR Clin Trans Res.* 2022:23800844211071111.  
771 Epub 20220222. doi: 10.1177/23800844211071111. PubMed PMID: 35191352.
- 772 67. Hajek A, Nedjad M, Kretzler B, König HH. [Use of and Attitudes toward Tests for  
773 the Detection of SARS-CoV-2 and Corresponding Antibodies: Results of a Nationally  
774 Representative Survey in Late Summer 2021]. *Gesundheitswesen.* 2023;85(1):26-35.  
775 Epub 20220909. doi: 10.1055/a-1916-9895. PubMed PMID: 36084943.
- 776 68. Fishman J, Bien-Gund CH, Bisson GP, Baik Y. COVID-19 Self-Testing  
777 Preferences Linked to Political Perspectives: Social Determinants in the U.S. Pandemic.

- 778 Am J Prev Med. 2022. Epub 20221103. doi: 10.1016/j.amepre.2022.09.024. PubMed  
779 PMID: 36411144; PubMed Central PMCID: PMC9630136.
- 780 69. Wu F, Yuan Y, Li Y, Yin D, Lang B, Zhao Y, et al. The acceptance of SARS-CoV-  
781 2 rapid antigen self-testing: A cross-sectional study in China. J Med Virol.  
782 2023;95(1):e28227. Epub 20221025. doi: 10.1002/jmv.28227. PubMed PMID:  
783 36241424.
- 784 70. Jairoun AA, Al Hemyari SS, Abdulla NM, Shahwan M, Bilal FHJ, Al-Tamimi SK,  
785 et al. Acceptability and Willingness of UAE Residents to Use OTC Vending Machines to  
786 Deliver Self-Testing Kits for COVID-19 and the Implications. J Multidiscip Healthc.  
787 2022;15:1759-70. doi: 10.2147/JMDH.S370441.
- 788 71. Wachinger J, Schirmer M, Tauber N, McMahon SA, Denking CM. Experiences  
789 with opt-in, at-home screening for SARS-CoV-2 at a primary school in Germany: An  
790 implementation study. BMJ Paediatr Open. 2021;5(1) (no pagination). doi:  
791 <https://dx.doi.org/10.1136/bmjpo-2021-001262>. PubMed PMID: 636301367.
- 792 72. Dallera G, Alaa A, El-Osta A, Kreindler J, Harris M. Evaluating the feasibility and  
793 acceptability of a safety protocol to mitigate SARS-CoV-2 transmission risks when  
794 participating in full-capacity live mass events: a cross-sectional survey and interview-  
795 based study. BMJ Open. 2022;12(12):e063838. Epub 20221223. doi: 10.1136/bmjopen-  
796 2022-063838. PubMed PMID: 36564106; PubMed Central PMCID: PMC9791109.
- 797 73. Woloshin S, Dewitt B, Krishnamurti T, Fischhoff B. Assessing How Consumers  
798 Interpret and Act on Results From At-Home COVID-19 Self-test Kits A Randomized  
799 Clinical Trial. JAMA Intern Med. doi: 10.1001/jamainternmed.2021.8075. PubMed  
800 PMID: WOS:000750999100004.
- 801 74. Bien-Gund C, Dugosh K, Acri T, Brady K, Thirumurthy H, Fishman J, et al.  
802 Factors Associated With US Public Motivation to Use and Distribute COVID-19 Self-  
803 tests. JAMA Netw Open. 2021;4(1):e2034001. Epub 20210104. doi:  
804 10.1001/jamanetworkopen.2020.34001. PubMed PMID: 33471114; PubMed Central  
805 PMCID: PMC9424120.
- 806 75. D'Agostino EM, Corbie G, Kibbe WA, Hornik CP, Richmond A, Dunston A, et al.  
807 Increasing access and uptake of SARS-CoV-2 at-home tests using a community-  
808 engaged approach. Prev Med Rep. 2022;29:101967. Epub 20220830. doi:  
809 10.1016/j.pmedr.2022.101967. PubMed PMID: 36061814; PubMed Central PMCID:  
810 PMC9424120.
- 811 76. Mouliou DS, Pantazopoulos I, Gourgoulis KI. Societal Criticism towards  
812 COVID-19: Assessing the Theory of Self-Diagnosis Contrasted to Medical Diagnosis.  
813 Diagnostics (Basel). 2021;11(10). Epub 20210927. doi: 10.3390/diagnostics11101777.  
814 PubMed PMID: 34679475; PubMed Central PMCID: PMC9424120.

- 815 77. Thomas C, Shilton S, Thomas C, Iye CM, Martínez-Pérez G. COVID-19 self-  
816 testing, a way to “live side by side with the coronavirus”: results from a qualitative study  
817 in Indonesia. *Res Sq.* 2022. doi: 10.21203/rs.3.rs-1304157/v1. PubMed PMID:  
818 PPR449862.
- 819 78. Willeit P, Bernar B, Zurl C, Al-Rawi M, Berghold A, Bernhard D, et al. Sensitivity  
820 and specificity of the antigen-based anterior nasal self-testing programme for detecting  
821 SARS-CoV-2 infection in schools, Austria, March 2021. *Euro Surveill.* 2021;26(34). doi:  
822 10.2807/1560-7917.ES.2021.26.34.2100797. PubMed PMID: WOS:000689672400002.
- 823 79. Nwaozuru U, Obiezu-Umeh C, Diallo H, Graham D, Whembolua GL, Bourgeau  
824 MJ, et al. Perceptions of COVID-19 self-testing and recommendations for  
825 implementation and scale-up among Black/African Americans: implications for the  
826 COVID-19 STEP project. *Bmc public health.* 2022;22(1). doi: 10.1186/s12889-022-  
827 13619-6. PubMed PMID: WOS:000813757700001.
- 828 80. Rader B, Gertz A, Iuliano AD, Gilmer M, Wronski L, Astley CM, et al. Use of At-  
829 Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022. *MMWR Morb*  
830 *Mortal Wkly Rep.* 2022;71(13):489-94. Epub 20220401. doi:  
831 10.15585/mmwr.mm7113e1. PubMed PMID: 35358168; PubMed Central PMCID:  
832 PMCPMC8979595.
- 833 81. Goggolidou P, Hodges-Mameletzis I, Purewal S, Karakoula A, Warr T. Self-  
834 Testing as an Invaluable Tool in Fighting the COVID-19 Pandemic. *J Prim Care*  
835 *Community Health.* 2021;12:21501327211047782. doi: 10.1177/21501327211047782.  
836 PubMed PMID: 34583571; PubMed Central PMCID: PMCPMC8485257.
- 837 82. Tulloch JSP, Micocci M, Buckle P, Lawrenson K, Kierkegaard P, McLister A, et  
838 al. Enhanced lateral flow testing strategies in care homes are associated with poor  
839 adherence and were insufficient to prevent COVID-19 outbreaks: results from a mixed  
840 methods implementation study. *Age Ageing.* 2021;50(6):1868-75. doi:  
841 10.1093/ageing/afab162.
- 842 83. Undelikwo V, Shilton S, Folayan MO, Alaba O, Reipold EI, Martínez-Pérez G.  
843 COVID-19 self-testing in Nigeria: Stakeholders’ opinions and perspective on its value for  
844 case detection. *medRxiv.* 2022. doi: 10.1101/2022.01.28.22269743. PubMed PMID:  
845 PPR447979.
- 846 84. Herbert C, Shi Q, Kheterpal V, Nowak C, Suvarna T, Durnan B, et al. Use of a  
847 Digital Assistant to Report COVID-19 Rapid Antigen Self-test Results to Health  
848 Departments in 6 US Communities. *JAMA Netw Open.* 2022;5(8):e2228885. Epub  
849 20220801. doi: 10.1001/jamanetworkopen.2022.28885. PubMed PMID: 36018589;  
850 PubMed Central PMCID: PMCPMC9419013.

- 851 85. Mina MJ, Peto TE, García-Fiñana M, Semple MG, Buchan IE. Clarifying the  
852 evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19.  
853 Lancet. 2021;397(10283):1425-7. doi: 10.1016/S0140-6736(21)00425-6.
- 854 86. McGuire M, de Waal A, Karellis A, Janssen R, Engel N, Sampath R, et al. HIV  
855 self-testing with digital supports as the new paradigm: A systematic review of global  
856 evidence (2010&#x2013;2021). eClinicalMedicine. 2021;39. doi:  
857 10.1016/j.eclinm.2021.101059. PubMed PMID: 101059.
- 858 87. Ritchey MD, Rosenblum HG, Del Guercio K, Humbard M, Santos S, Hall J, et al.  
859 COVID-19 Self-Test Data: Challenges and Opportunities - United States, October 31,  
860 2021-June 11, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(32):1005-10. Epub  
861 20220812. doi: 10.15585/mmwr.mm7132a1. PubMed PMID: 35951486; PubMed  
862 Central PMCID: PMC9400539.
- 863 88. LLC N. COVID-19 Diagnostic Self-testing Using Virtual Point-of-care:  
864 ClinicalTrials.gov; 2020. Available from:  
865 <https://clinicaltrials.gov/ct2/show/NCT04348864>.
- 866 89. Robert Gross UoP. COVID-19 Self-Testing Through Rapid Network Distribution  
867 (C-STRAND): ClinicalTrials.gov; 2021. Available from:  
868 <https://clinicaltrials.gov/ct2/show/NCT04797858>.
- 869 90. Zahavi M, Rohana H, Azrad M, Shinberg B, Peretz A. Rapid SARS-CoV-2  
870 Detection Using the Lucira™ Check It COVID-19 Test Kit. Diagnostics (Basel).  
871 2022;12(8). Epub 20220803. doi: 10.3390/diagnostics12081877. PubMed PMID:  
872 36010227; PubMed Central PMCID: PMC9406928.

873

## 874 **Supporting information**

875 **S1 Box. Search String.**

876 **S1 Table. Outcomes Description.**

877 **S2 Table. Study Characteristics.**

878 **S3 Table. Diagnostic accuracy across test devices.**


879 **S1 Fig A and B. Forest Plot.**

880 **S2 Fig A-D. Comparison of summary receiver operating characteristic (SROC) curves.**

881 **S3 Fig. Funnel Plot of studies included in the meta-analysis (n=14).**

882 **S4 Table A-C. Risk of bias.**

Figure 1: PRISMA flow diagram



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <http://www.prisma-statement.org/>

Figure 1